AnaptysBio’s imsidolimab an Orphan Drug in U.S. for rare type of psoriasis

The FDA designates AnaptysBio’s (ANAB +0.5%) imsidolimab, an interleukin-36 receptor (IL-36R) inhibitor, an Orphan Drug for the treatment of patients with generalized pustular psoriasis (GPP), a very rare form of psoriasis characterized by pus-filled blisters on the skin.

Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.

https://seekingalpha.com/news/3589661-anaptysbios-imsidolimab-orphan-drug-in-u-s-for-rare-type-of-psoriasis